Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

The Molecular Basis of Herpesviruses as Oncolytic Agents

Author(s): Laura Menotti, Gabriella Campadelli-Fiume, Patrizia Nanni, Pier Luigi Lollini and Carla De Giovanni

Volume 13, Issue 9, 2012

Page: [1795 - 1803] Pages: 9

DOI: 10.2174/138920112800958931

Price: $65

conference banner
Abstract

Herpes simplex viruses (HSVs) have entered clinical trials as oncolytic agents. The following properties make them good candidates. It is a mild pathogen; drugs (Aciclovir) are available to control viral infection; the large genome is amenable to genetic engineering, they can be rendered cancer-specific by deletion of genes, envelope glycoproteins allow the insertion of heterologous ligands to achieve modification of the natural tropism. Genetically modified HSVs have been thoroughly tested in humans. New generation recombinants retargeted to cancer-specific heterologous receptors have been generated and are presently evaluated in pre-clinical settings. They will be reviewed along with the molecular bases of cancer specificity and the strategies for the enhancement of oncolytic potential of HSV recombinants.

Keywords: Herpes simplex virus, oncolytic virus, oncolytic virotherapy, glioma, γ1 34.5, HER-2, mild pathogen, natural tropism, cancer specificity, HSV recombinants


Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy